Form 8-K - Current report:
SEC Accession No. 0000950170-23-003293
Filing Date
2023-02-21
Accepted
2023-02-21 07:00:45
Documents
13
Period of Report
2023-02-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20230217.htm   iXBRL 8-K 64099
2 EX-10.1 clsd-ex10_1.htm EX-10 153200
  Complete submission text file 0000950170-23-003293.txt   356100

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT clsd-20230217_lab.xml EX-101.LAB 13360
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT clsd-20230217_pre.xml EX-101.PRE 9843
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT clsd-20230217.xsd EX-101.SCH 2469
7 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20230217_htm.xml XML 4717
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 23645214
SIC: 2834 Pharmaceutical Preparations